

Chung Yin Kong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/684971/publications.pdf>

Version: 2024-02-01

109
papers

5,269
citations

117625

34
h-index

91884

69
g-index

110
all docs

110
docs citations

110
times ranked

6205
citing authors

#	ARTICLE	IF	CITATIONS
1	The Effect of Advances in Lung-Cancer Treatment on Population Mortality. <i>New England Journal of Medicine</i> , 2020, 383, 640-649.	27.0	893
2	Trends in esophageal adenocarcinoma incidence and mortality. <i>Cancer</i> , 2013, 119, 1149-1158.	4.1	439
3	Benefits and Harms of Computed Tomography Lung Cancer Screening Strategies: A Comparative Modeling Study for the U.S. Preventive Services Task Force. <i>Annals of Internal Medicine</i> , 2014, 160, 311.	3.9	377
4	Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study. <i>PLoS Medicine</i> , 2017, 14, e1002277.	8.4	216
5	Cost-Effectiveness of Computed Tomography Screening for Lung Cancer in the United States. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1841-1848.	1.1	213
6	Evaluation of the Benefits and Harms of Lung Cancer Screening With Low-Dose Computed Tomography. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 988.	7.4	181
7	Smoking and Lung Cancer Mortality in the United States From 2015 to 2065. <i>Annals of Internal Medicine</i> , 2018, 169, 684.	3.9	150
8	Impact of Reduced Tobacco Smoking on Lung Cancer Mortality in the United States During 1975â€“2000. <i>Journal of the National Cancer Institute</i> , 2012, 104, 541-548.	6.3	145
9	The Cost Effectiveness of Radiofrequency Ablation for Barrett's Esophagus. <i>Gastroenterology</i> , 2012, 143, 567-575.	1.3	143
10	Disparities in cancer outcomes across age, sex, and race/ethnicity among patients with pancreatic cancer. <i>Cancer Medicine</i> , 2018, 7, 525-535.	2.8	136
11	Calibration Methods Used in Cancer Simulation Models and Suggested Reporting Guidelines. <i>Pharmacoeconomics</i> , 2009, 27, 533-545.	3.3	99
12	Lung Cancer Mortality Associated With Smoking and Smoking Cessation Among People Living With HIV in the United States. <i>JAMA Internal Medicine</i> , 2017, 177, 1613.	5.1	99
13	Estimating Long-term Effectiveness of Lung Cancer Screening in the Mayo CT Screening Study. <i>Radiology</i> , 2008, 248, 278-287.	7.3	94
14	Cost-Effectiveness Analysis of Lung Cancer Screening in the United States. <i>Annals of Internal Medicine</i> , 2019, 171, 796.	3.9	81
15	Development and Validation of a Multivariable Lung Cancer Risk Prediction Model That Includes Low-Dose Computed Tomography Screening Results. <i>JAMA Network Open</i> , 2019, 2, e190204.	5.9	70
16	A Comparative Modeling Analysis of Risk-Based Lung Cancer Screening Strategies. <i>Journal of the National Cancer Institute</i> , 2020, 112, 466-479.	6.3	67
17	Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials. <i>Cancer</i> , 2014, 120, 1713-1724.	4.1	65
18	Exploring the Recent Trend in Esophageal Adenocarcinoma Incidence and Mortality Using Comparative Simulation Modeling. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 997-1006.	2.5	61

#	ARTICLE	IF	CITATIONS
19	Aspirin Protects Against Barrett's Esophagus in a Multivariate Logistic Regression Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 722-727.	4.4	57
20	Lung cancer costs by treatment strategy and phase of care among patients enrolled in Medicare. <i>Cancer Medicine</i> , 2019, 8, 94-103.	2.8	54
21	Convergent Evolution of Novel Protein Function in Shrew and Lizard Venom. <i>Current Biology</i> , 2009, 19, 1925-1931.	3.9	53
22	Calibration of Disease Simulation Model Using an Engineering Approach. <i>Value in Health</i> , 2009, 12, 521-529.	0.3	53
23	Cost Effectiveness of Screening Patients With Gastroesophageal Reflux Disease for Barrett's Esophagus With a Minimally Invasive Cell Sampling Device. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1397-1404.e7.	4.4	51
24	Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System. <i>JAMA Oncology</i> , 2019, 5, 358.	7.1	48
25	Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States. <i>JAMA Network Open</i> , 2019, 2, e1911952.	5.9	47
26	Cancer Risk in Subsolid Nodules in the National Lung Screening Trial. <i>Radiology</i> , 2019, 293, 441-448.	7.3	47
27	The Impact of a Prior Diagnosis of Barrett's Esophagus on Esophageal Adenocarcinoma Survival. <i>American Journal of Gastroenterology</i> , 2017, 112, 1256-1264.	0.4	45
28	The Impact of Obesity on the Rise in Esophageal Adenocarcinoma Incidence: Estimates from a Disease Simulation Model. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 2450-2456.	2.5	38
29	Comparing Benefits from Many Possible Computed Tomography Lung Cancer Screening Programs: Extrapolating from the National Lung Screening Trial Using Comparative Modeling. <i>PLoS ONE</i> , 2014, 9, e99978.	2.5	38
30	Racial/ethnic disparities in colorectal cancer treatment utilization and phase-specific costs, 2000-2014. <i>PLoS ONE</i> , 2020, 15, e0231599.	2.5	38
31	Simulations of Stochastic Sensing of Proteins. <i>Journal of the American Chemical Society</i> , 2005, 127, 18252-18261.	13.7	37
32	Chapter 9: The MGH-HMS Lung Cancer Policy Model: Tobacco Control Versus Screening. <i>Risk Analysis</i> , 2012, 32, S117-24.	2.7	37
33	Effect and cost-effectiveness of national gastric cancer screening in Japan: a microsimulation modeling study. <i>BMC Medicine</i> , 2020, 18, 257.	5.5	37
34	The impact of overdiagnosis on the selection of efficient lung cancer screening strategies. <i>International Journal of Cancer</i> , 2017, 140, 2436-2443.	5.1	36
35	Patients with Testicular Cancer Undergoing CT Surveillance Demonstrate a Pitfall of Radiation-induced Cancer Risk Estimates: The Timing Paradox. <i>Radiology</i> , 2013, 266, 896-904.	7.3	35
36	Benefits and harms of lung cancer screening in HIV-infected individuals with CD4+ cell count at least 500 cells/ μ l. <i>Aids</i> , 2018, 32, 1333-1342.	2.2	35

#	ARTICLE	IF	CITATIONS
37	Projected Costs, Risks, and Benefits of Expanded Newborn Screening for MCADD. <i>Pediatrics</i> , 2010, 125, e286-e294.	2.1	34
38	Targeted Screening of Individuals at High Risk for Pancreatic Cancer: Results of a Simulation Model. <i>Radiology</i> , 2015, 275, 177-187.	7.3	34
39	Cost-Effectiveness of Smoking Cessation Interventions in the Lung Cancer Screening Setting: A Simulation Study. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1065-1073.	6.3	34
40	Early Pancreatic Ductal Adenocarcinoma Survival Is Dependent on Size. <i>Pancreas</i> , 2016, 45, 1062-1066.	1.1	33
41	Quality-of-Life Assessment of Fibroid Treatment Options and Outcomes. <i>Radiology</i> , 2011, 259, 785-792.	7.3	32
42	Progression to pancreatic ductal adenocarcinoma from pancreatic intraepithelial neoplasia: Results of a simulation model. <i>Pancreatology</i> , 2018, 18, 928-934.	1.1	32
43	Using Radiation Risk Models in Cancer Screening Simulations: Important Assumptions and Effects on Outcome Projections. <i>Radiology</i> , 2012, 262, 977-984.	7.3	30
44	Adopting helical CT screening for lung cancer. <i>Cancer</i> , 2008, 113, 3440-3449.	4.1	29
45	Cost-effectiveness Evaluation of the 2021 US Preventive Services Task Force Recommendation for Lung Cancer Screening. <i>JAMA Oncology</i> , 2021, 7, 1833.	7.1	29
46	Statins and Aspirin for Chemoprevention in Barrett's Esophagus: Results of a Cost-Effectiveness Analysis. <i>Cancer Prevention Research</i> , 2014, 7, 341-350.	1.5	27
47	Disparities and Trends in Genetic Testing and Erlotinib Treatment among Metastatic Non-Small Cell Lung Cancer Patients. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 926-934.	2.5	27
48	The effect of radiographic emphysema in assessing lung cancer risk. <i>Thorax</i> , 2019, 74, 858-864.	5.6	24
49	Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US. <i>JAMA Network Open</i> , 2020, 3, e2016144.	5.9	24
50	JOURNAL CLUB: How Radiation Exposure Histories Influence Physician Imaging Decisions: A Multicenter Radiologist Survey Study. <i>American Journal of Roentgenology</i> , 2013, 200, 1275-1283.	2.2	23
51	Personalizing annual lung cancer screening for patients with chronic obstructive pulmonary disease: A decision analysis. <i>Cancer</i> , 2015, 121, 1556-1562.	4.1	23
52	Esophageal cancer treatment costs by phase of care and treatment modality, 2000-2013. <i>Cancer Medicine</i> , 2019, 8, 5158-5172.	2.8	21
53	Population impact of lung cancer screening in the United States: Projections from a microsimulation model. <i>PLoS Medicine</i> , 2018, 15, e1002506.	8.4	21
54	Radiofrequency Ablation of Barrett's Esophagus Reduces Esophageal Adenocarcinoma Incidence and Mortality in a Comparative Modeling Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1471-1474.	4.4	20

#	ARTICLE	IF	CITATIONS
55	Patterns and predictors of end-of-life care in older patients with pancreatic cancer. <i>Cancer Medicine</i> , 2018, 7, 6401-6410.	2.8	20
56	Cost and Utilization of Lung Cancer End-of-Life Care Among Racial-Ethnic Minority Groups in the United States. <i>Oncologist</i> , 2020, 25, e120-e129.	3.7	20
57	Survival Disparities by Race and Ethnicity in Early Esophageal Cancer. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2880-2888.	2.3	18
58	Identifying Best-Fitting Inputs in Health-Economic Model Calibration. <i>Medical Decision Making</i> , 2015, 35, 170-182.	2.4	17
59	Surgical vs Endoscopic Management of T1 Esophageal Adenocarcinoma: A Modeling Decision Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 392-400.e7.	4.4	17
60	A Decision Analysis of Follow-up and Treatment Algorithms for Nonsolid Pulmonary Nodules. <i>Radiology</i> , 2019, 290, 506-513.	7.3	17
61	Patient and Societal Value Functions for the Testing Morbidities Index. <i>Medical Decision Making</i> , 2013, 33, 819-838.	2.4	16
62	Evaluating the impacts of screening and smoking cessation programmes on lung cancer in a high-burden region of the USA: a simulation modelling study. <i>BMJ Open</i> , 2016, 6, e010227.	1.9	16
63	Hospice use and end-of-life care among older patients with esophageal cancer. <i>Health Science Reports</i> , 2018, 1, e76.	1.5	16
64	Factors Influencing the False Positive Rate in CT Lung Cancer Screening. <i>Academic Radiology</i> , 2022, 29, S18-S22.	2.5	16
65	Development, Calibration, and Validation of a U.S. White Male Population-Based Simulation Model of Esophageal Adenocarcinoma. <i>PLoS ONE</i> , 2010, 5, e9483.	2.5	15
66	Optimizing Management of Patients With Barrett's Esophagus and Low-Grade or No Dysplasia Based on Comparative Modeling. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1961-1969.	4.4	15
67	Screening for Pancreatic Adenocarcinoma in BRCA2 Mutation Carriers: Results of a Disease Simulation Model. <i>EBioMedicine</i> , 2015, 2, 1980-1986.	6.1	14
68	Initial development of the Temporary Utilities Index: a multiattribute system for classifying the functional health impact of diagnostic testing. <i>Quality of Life Research</i> , 2010, 19, 401-412.	3.1	13
69	High-resolution microendoscopy for esophageal cancer screening in China: A cost-effectiveness analysis. <i>World Journal of Gastroenterology</i> , 2015, 21, 5513.	3.3	13
70	Pancreatic cancer treatment costs, including patient liability, by phase of care and treatment modality, 2000-2013. <i>Medicine (United States)</i> , 2019, 98, e18082.	1.0	13
71	Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis. <i>Oncologist</i> , 2019, 24, 945-954.	3.7	13
72	A simulation model of colorectal cancer surveillance and recurrence. <i>BMC Medical Informatics and Decision Making</i> , 2014, 14, 29.	3.0	12

#	ARTICLE	IF	CITATIONS
73	Comparing Morbidities of Testing With a New Index: Screening Colonoscopy Versus Core-Needle Breast Biopsy. <i>Journal of the American College of Radiology</i> , 2015, 12, 295-301.	1.8	12
74	Effect of PD-L1 testing on the cost-effectiveness and budget impact of pembrolizumab for advanced urothelial carcinoma of the bladder in the United States. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 180.e11-180.e18.	1.6	12
75	Cost-effectiveness of pembrolizumab for advanced non-small cell lung cancer patients with varying comorbidity burden. <i>PLoS ONE</i> , 2020, 15, e0228288.	2.5	12
76	Microsimulation Model Predicts Survival Benefit of Radiofrequency Ablation and Stereotactic Body Radiotherapy Versus Radiotherapy for Treating Inoperable Stage I Non-Small Cell Lung Cancer. <i>American Journal of Roentgenology</i> , 2013, 200, 1020-1027.	2.2	11
77	Imaging for Appendicitis: Should Radiation-induced Cancer Risks Affect Modality Selection?. <i>Radiology</i> , 2014, 273, 472-482.	7.3	10
78	Short-term outcomes for lung cancer resection surgery in HIV infection. <i>Aids</i> , 2019, 33, 1353-1360.	2.2	9
79	Performance of Lung Nodule Management Algorithms for Lung-RADS Category 4 Lesions. <i>Academic Radiology</i> , 2020, 28, 1037-1042.	2.5	9
80	Cost-Effectiveness of Follow-Up for Subsolid Pulmonary Nodules in High-Risk Patients. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1298-1305.	1.1	9
81	Cost-Effectiveness of Treatment Thresholds for Subsolid Pulmonary Nodules in CT Lung Cancer Screening. <i>Radiology</i> , 2021, 300, 586-593.	7.3	9
82	Evaluating lung cancer screening in China: Implications for eligibility criteria design from a microsimulation modeling approach. <i>PLoS ONE</i> , 2017, 12, e0173119.	2.5	9
83	Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategies. <i>PLoS ONE</i> , 2019, 14, e0215409.	2.5	7
84	Endoscopic Screening Program for Control of Esophageal Adenocarcinoma in Varied Populations: A Comparative Cost-Effectiveness Analysis. <i>Gastroenterology</i> , 2022, 163, 163-173.	1.3	7
85	Optimal treatment strategies for stage I non-small cell lung cancer in veterans with pulmonary and cardiac comorbidities. <i>PLoS ONE</i> , 2021, 16, e0248067.	2.5	6
86	Assessment of treatment strategies for stage I non-small cell lung cancer in patients with comorbidities. <i>Lung Cancer</i> , 2022, 170, 34-40.	2.0	6
87	The thyroid cancer policy model: A mathematical simulation model of papillary thyroid carcinoma in The U.S. population. <i>PLoS ONE</i> , 2017, 12, e0177068.	2.5	5
88	A simulation study of the effect of lung cancer screening in China, Japan, Singapore, and South Korea. <i>PLoS ONE</i> , 2019, 14, e0220610.	2.5	5
89	Combined Biomarker and Computed Tomography Screening Strategies for Lung Cancer. <i>MDM Policy and Practice</i> , 2016, 1, 238146831664396.	0.9	4
90	Analysis of factors associated with extended recovery time after colonoscopy. <i>PLoS ONE</i> , 2018, 13, e0199246.	2.5	4

#	ARTICLE	IF	CITATIONS
91	Testing for Verification Bias in Reported Malignancy Risks for Side-Branch Intraductal Papillary Mucinous Neoplasms: A Simulation Modeling Approach. American Journal of Roentgenology, 2019, 212, 596-601.	2.2	4
92	Cost-Effectiveness of Follow-Up Ultrasound for Incidental Thyroid Nodules on CT. American Journal of Roentgenology, 2022, 218, 615-622.	2.2	4
93	Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in borderline resectable/locally advanced pancreatic cancer patients. Cancer Reports, 2022, 5, e1565.	1.4	4
94	Development and validation of a model to predict outcomes of colon cancer surveillance. Cancer Causes and Control, 2019, 30, 767-778.	1.8	3
95	Lung cancer incidence among world trade center rescue and recovery workers. Cancer Medicine, 2022, 11, 3136-3144.	2.8	3
96	Impact of Comorbidities on Lung Cancer Screening Evaluation. Clinical Lung Cancer, 2022, 23, 402-409.	2.6	3
97	Cost-Effectiveness Analysis of Lung Cancer Screening in the United States. Annals of Internal Medicine, 2020, 172, 706-707.	3.9	2
98	Cost-Effectiveness of Management Algorithms for Lung-RADS Category 4 Nodules. Radiology: Cardiothoracic Imaging, 2021, 3, e200523.	2.5	2
99	Risk of Cardiovascular Toxicity According to Tumor Laterality Among Older Patients With Early Stage Non-small Cell Lung Cancer Treated With Radiation Therapy. Chest, 2022, 161, 1666-1674.	0.8	2
100	Changes to Model Assumptions of the Cost-effectiveness of Durvalumab Therapy for Non-Small Cell Lung Cancer—In Reply. JAMA Oncology, 2019, 5, 1066.	7.1	1
101	Tissue scale agent-based simulation of premalignant progressions in Barrett's esophagus. Simulation, 2020, 10, 003754972110400.	1.8	1
102	Cost-effectiveness of immune checkpoint inhibition in metastatic gastric and esophageal tumors.. Journal of Clinical Oncology, 2018, 36, 56-56.	1.6	1
103	Re: Think before you leap. International Journal of Cancer, 2018, 142, 1507-1509.	5.1	0
104	Cost-effectiveness analysis of platinum-based chemotherapy treatment options for germline BRCA-mutated locally advanced/borderline resectable pancreatic cancer.. Journal of Clinical Oncology, 2021, 39, e16246-e16246.	1.6	0
105	Neoadjuvant FOLFIRINOX for patients with borderline resectable or locally advanced pancreatic cancer: Results of a decision analysis.. Journal of Clinical Oncology, 2017, 35, 4117-4117.	1.6	0
106	Disparities in cancer outcomes across age, sex, and race/ethnicity among pancreatic cancer patients.. Journal of Clinical Oncology, 2017, 35, e18071-e18071.	1.6	0
107	Cost-effectiveness of single versus dual immune checkpoint blockade for chemotherapy-refractory esophageal, GE junction, and gastric cancers.. Journal of Clinical Oncology, 2018, 36, e16089-e16089.	1.6	0
108	Optimizing the use of adjuvant chemotherapy in non-small cell lung cancer patients with comorbidities. Current Problems in Cancer, 2022, , 100867.	2.0	0

#	ARTICLE	IF	CITATIONS
109	Lung cancer treatment patterns in patients with diabetes.. Journal of Clinical Oncology, 2022, 40, e18723-e18723.	1.6	0